Search Results - "Groot, Jan Willem B."

Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma by Kelderman, Sander, Heemskerk, Bianca, van Tinteren, Harm, van den Brom, Rob R. H., Hospers, Geke A. P., van den Eertwegh, Alfonsus J. M., Kapiteijn, Ellen W., de Groot, Jan Willem B., Soetekouw, Patricia, Jansen, Rob L., Fiets, Edward, Furness, Andrew J. S., Renn, Alexandra, Krzystanek, Marcin, Szallasi, Zoltan, Lorigan, Paul, Gore, Martin E., Schumacher, Ton N. M., Haanen, John B. A. G., Larkin, James M. G., Blank, Christian U.

“…Introduction Ipilimumab, a cytotoxic T lymphocyte-associated antigen-4 blocking antibody, has improved overall survival (OS) in metastatic melanoma in phase…”
Get full text

Safety and Feasibility of Additional Tumor Debulking to First‐Line Palliative Combination Chemotherapy for Patients with Multiorgan Metastatic Colorectal Cancer by Gootjes, Elske C., Stok, Eric P., Buffart, Tineke E., Bakkerus, Lotte, Labots, Mariette, Zonderhuis, Barbara M., Tuynman, Jurriaan B., Meijerink, Martijn R., Ven, Peter M., Haasbeek, Cornelis J.A., ten Tije, Albert J., Groot, Jan‐Willem B., Hendriks, Mathijs P., Meerten, Esther, Nuyttens, Joost J.M.E., Grunhagen, Dirk J., Verhoef, Cornelis, Verheul, Henk M.W.

“…Introduction Local treatment of metastases is frequently performed in patients with multiorgan metastatic colorectal carcinoma (mCRC) analogous to selected…”
Get full text

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial by Dummer, Reinhard, Ascierto, Paolo A, Gogas, Helen J, Arance, Ana, Mandala, Mario, Liszkay, Gabriella, Garbe, Claus, Schadendorf, Dirk, Krajsova, Ivana, Gutzmer, Ralf, Chiarion-Sileni, Vanna, Dutriaux, Caroline, de Groot, Jan Willem B, Yamazaki, Naoya, Loquai, Carmen, Moutouh-de Parseval, Laure A, Pickard, Michael D, Sandor, Victor, Robert, Caroline, Flaherty, Keith T

“…Combined BRAF-MEK inhibitor therapy is the standard of care for BRAFV600-mutant advanced melanoma. We investigated encorafenib, a BRAF inhibitor with unique…”
Get full text

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial by Dummer, Reinhard, Ascierto, Paolo A, Gogas, Helen J, Arance, Ana, Mandala, Mario, Liszkay, Gabriella, Garbe, Claus, Schadendorf, Dirk, Krajsova, Ivana, Gutzmer, Ralf, Chiarion Sileni, Vanna, Dutriaux, Caroline, de Groot, Jan Willem B, Yamazaki, Naoya, Loquai, Carmen, Moutouh-de Parseval, Laure A, Pickard, Michael D, Sandor, Victor, Robert, Caroline, Flaherty, Keith T

“…Encorafenib plus binimetinib and encorafenib alone improved progression-free survival compared with vemurafenib in patients with BRAFV600-mutant melanoma in…”
Get full text

The Effects of Four Different Tyrosine Kinase Inhibitors on Medullary and Papillary Thyroid Cancer Cells by Verbeek, Hans H. G, Alves, Maria M, de Groot, Jan-Willem B, Osinga, Jan, Plukker, John T. M, Links, Thera P, Hofstra, Robert M. W

“…Tyrosine kinase inhibitor therapy for medullary and papillary thyroid carcinoma is mutation specific, with XL184 being the most potent inhibitor in MEN2A and…”
Get full text

Sex, Gender and Age Differences in Treatment Allocation and Survival of Patients With Metastatic Pancreatic Cancer: A Nationwide Study by Pijnappel, Esther N, Schuurman, Melinda, Wagner, Anna D, de Vos-Geelen, Judith, van der Geest, Lydia G M, de Groot, Jan-Willem B, Koerkamp, Bas Groot, de Hingh, Ignace H J T, Homs, Marjolein Y V, Creemers, Geert-Jan, Cirkel, Geert A, van Santvoort, Hjalmar C, Busch, Olivier R, Besselink, Marc G, van Eijck, Casper H J, Wilmink, Johanna W, van Laarhoven, Hanneke W M

“…Biological sex, gender and age have an impact on the incidence and outcome in patients with metastatic pancreatic cancer. The aim of this study is to…”
Get full text

Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma by Ascierto, Paolo A., Dummer, Reinhard, Gogas, Helen J., Flaherty, Keith T., Arance, Ana, Mandala, Mario, Liszkay, Gabriella, Garbe, Claus, Schadendorf, Dirk, Krajsova, Ivana, Gutzmer, Ralf, de Groot, Jan Willem B., Loquai, Carmen, Gollerkeri, Ashwin, Pickard, Michael D., Robert, Caroline

“…BRAF/MEK inhibitor combinations are established treatments for BRAF V600–mutant melanoma based on demonstrated benefits on progression-free survival (PFS) and…”
Get full text

Tolerability of Capecitabine Monotherapy in Metastatic Colorectal Cancer: A Real-World Study by Leicher, Laura W., de Graaf, Jacques C., Coers, Wilko, Tascilar, Metin, de Groot, Jan Willem B.

“…Background Capecitabine monotherapy is a treatment option for selected patients with metastatic colorectal cancer (mCRC) and is administered to up to 17% of…”
Get full text

Factors Predicting Outcome of Total Thyroidectomy in Young Patients with Multiple Endocrine Neoplasia Type 2: A Nationwide Long-Term Follow-up Study by Schreinemakers, Jennifer M. J., Vriens, Menno R., Valk, Gerlof D., de Groot, Jan-Willem B., Plukker, John T., Bax, Klaas (N.) M. A., Hamming, Jaap F., van der Luijt, Rob B., Aronson, Daniel C., Borel Rinkes, Inne H. M.

“…Background Multiple endocrine neoplasia type 2 (MEN 2) is caused by a RET mutation in chromosome 10. All MEN 2 patients develop medullary thyroid carcinoma…”
Get full text

ASO Author Reflections: Intensified Neoadjuvant Chemoradiotherapy Followed by Esophagectomy in Esophageal Cancer by Boers, Jorianne, de Groot, Jan Willem B.

Get full text

Delayed TME Surgery in a Watch-and-Wait Strategy After Neoadjuvant Chemoradiotherapy for Rectal Cancer: An Analysis of Hospital Costs and Surgical and Oncological Outcomes by Meyer, Vincent M., Meuzelaar, Richtje R., Schoenaker, Ivonne J.H., de Groot, Jan-Willem B., Reerink, Onne, de Vos tot Nederveen Cappel, Wouter H., Beets, Geerard L., van Westreenen, Henderik L.

“…A watch-and-wait strategy for patients with rectal cancer with a clinical complete response after neoadjuvant chemoradiotherapy is a valuable alternative for…”
Get full text

Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma by van Not, Olivier J, Verheijden, Rik J, van den Eertwegh, Alfonsus J M, Haanen, John B A G, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Blank, Christian U, Boers-Sonderen, Marye J, de Groot, Jan-Willem B, Hospers, Geke A P, Kamphuis, Anna M, Kapiteijn, Ellen, May, Anne M, de Meza, Melissa M, Piersma, Djura, van Rijn, Rozemarijn, Stevense-den Boer, Marion A, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Blokx, Willeke A M, Wouters, Michel J M, Suijkerbuijk, Karijn P M

“…Management of checkpoint inhibitor-induced immune-related adverse events (irAEs) is primarily based on expert opinion. Recent studies have suggested…”
Get more information

Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies by Van Not, Olivier J., van den Eertwegh, Alfons J.M., Haanen, John B., van Rijn, Rozemarijn S., Aarts, Maureen J.B., van den Berkmortel, Franchette W.P.J., Blank, Christian U., Boers-Sonderen, Marye J., van Eijs, Mick J.M., de Groot, Jan-Willem B., Hospers, Geke A.P., Kapiteijn, Ellen, de Meza, Melissa, Piersma, Djura, Stevense-den Boer, Marion, van der Veldt, Astrid A.M., Vreugdenhil, Gerard, Wouters, Michel W.J.M., Suijkerbuijk, Karijn P.M., Blokx, Willeke A.M.

“…Patients diagnosed with haematologic malignancies (HMs) have a higher risk of developing subsequent solid tumours, such as melanoma. Patients with HM were…”
Get full text

Timing of start of systemic treatment in patients with asymptomatic metastasized pancreatic cancer (TIMEPAN): a protocol of a multicenter prospective patient preference non-randomized trial by Augustinus, Simone, Broekman, Thijmen, Creemers, Geert-Jan, Daamen, Lois A, van Dieren, Susan, de Groot, Jan-Willem B, Cirkel, Geert A, Homs, Marjolein Y V, van Laarhoven, Hanneke W M, van Leeuwen, Lobke, Los, Maartje, Luelmo, Saskia A C, van Oijen, Martijn G H, Spierings, Leontine E A M, de Vos-Geelen, Judith, Besselink, Marc G, Wilmink, Johanna W

Get more information

Severe Immune-Related Enteritis after In Utero Exposure to Pembrolizumab by Baarslag, Manuel A., Heimovaara, Joosje H., Borgers, Jessica S.W., van Aerde, Koen J., Koenen, Hans J.P.M., Smeets, Ruben L., Buitelaar, Pauline L.M., Pluim, Dick, Vos, Shoko, Henriet, Stefanie S.V., de Groot, Jan Willem B., van Grotel, Martine, Rosing, Hilde, Beijnen, Jos H., Huitema, Alwin D.R., Haanen, John B.A.G., Amant, Frédéric, Gierenz, Nicole

“…Immune checkpoint blockade has become standard treatment for many types of cancer. Such therapy is indicated most often in patients with advanced or metastatic…”
Get full text

Intensified Neoadjuvant Chemoradiotherapy for Patients with Potentially Resectable Esophageal Cancer: A Retrospective Cohort Study by Boers, Jorianne, Joldersma, Annalie, van Dalsen, Annette D., Wiegman, Erwin M., Schenk, B. Ed, de Graaf, Jacques C., Pierik, Engelbertus G. J. M., Timmer, Paul R., de Groot, Jan Willem B.

“…Background Neoadjuvant treatment consisting of five cycles of carboplatin and paclitaxel with concurrent radiotherapy (41.4 Gy), followed by esophagectomy, is…”
Get full text

Added value of digital FDG-PET/CT in disease staging and restaging in patients with resectable or borderline resectable pancreatic cancer by de Jong, Tonke L., Koopman, Daniëlle, van der Worp, Corné A.J., Stevens, Henk, Vuijk, Floris A., Vahrmeijer, Alexander L., Mieog, J. Sven D., de Groot, Jan-Willem B., Meijssen, Maarten A.C., Nieuwenhuijs, Vincent B., de Geus-Oei, Lioe-Fee, Jager, Pieter L., Patijn, Gijs A.

“…We studied the added value of digital FDG-PET/CT in disease staging and restaging compared to the standard work-up with contrast enhanced CT (ceCT) and CA19-9…”
Get full text

Association between primary origin (head, body and tail) of metastasised pancreatic ductal adenocarcinoma and oncologic outcome: A population-based analysis by Mackay, Tara M., van Erning, Felice N., van der Geest, Lydia G.M., de Groot, Jan Willem B., Haj Mohammad, Nadia, Lemmens, Valery E., van Laarhoven, Hanneke W., Besselink, Marc G., Wilmink, Johanna W.

“…The relation between the primary origin of metastasised pancreatic ductal adenocarcinoma (PDAC)—head, body or tail—metastatic patterns and outcomes has not yet…”
Get full text

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis by van Breeschoten, Jesper, Wouters, Michel W. J. M., Hilarius, Doranne L., Haanen, John B., Blank, Christian U., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., de Groot, Jan-Willem B., Hospers, Geke A. P., Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S., Suijkerbuijk, Karijn P. M., Blokx, Willeke A. M., Tije, Bert-Jan J. ten, Veldt, Astrid A. M. van der, Vreugdenhil, Art, Boers-Sonderen, Marye J., van den Eertwegh, Alfonsus J. M.

Get full text

Early Recurrence in Completely Resected IIIB and IIIC Melanoma Warrants Restaging Prior to Adjuvant Therapy by Bloemendal, Martine, van Willigen, Wouter W., Bol, Kalijn F., Boers-Sonderen, Marye J., Bonenkamp, Johannes J., Werner, J. E. M., Aarntzen, Erik H. J. G., Koornstra, Rutger H. T., de Groot, Jan Willem B., de Vries, I. Jolanda M., van der Hoeven, Jacobus J. M., Gerritsen, Winald R., de Wilt, Johannes H. W.

“…Purpose To evaluate the results of restaging completely resected stage IIIB/C melanoma prior to start of adjuvant therapy. Patients and Methods One hundred…”
Get full text